Introduction
Glucocorticoids play important and complex roles in regulating carbohydrate, protein and lipid metabolism and may affect body mass index (BMI) through effects on hypothalamic peptides as well as on lipid metabolism and adipogenesis.
1,2 An Asn363Ser variant, caused by a single nucleotide difference (A1218G) in exon 2 of the glucocorticoid receptor gene (GRL), has shown association with increased sensitivity to glucocorticoids as well as a tendency towards increased BMI. 3 Furthermore, the GRL gene locus (5q31 -q32), encompassing also the beta-2-adrenergic receptor gene locus, has shown indications of linkage with variations in body weight in one study. 4 Recently, a study of 319 white Australians has shown a positive association of the Asn363Ser variant with an increase in BMI, conferring almost absolute likelihood of being overweight. 5 We have therefore tested whether this variant is associated with obesity, measured as BMI and waist -hip ratio or weight gain in a large, case-cohort study of Danish obese men.
Subjects, methods and results
The study population constitutes a case -cohort design based on selection of all obese cases (BMI ! 31 kg=m 2 ) among the young Danish men who, at around age 20 (range 18 -26 y), were examined at the draft board, and the selection of a random reference population as every 200th draftee in the same period. The cohort was further restricted to those among both groups who, in addition, were examined at the Copenhagen City Heart Study Programme in 1981 -1983 6 and again in 1992 -1994, an average of 27.4 AE 8.4 (s.d.) y after the draft board examination. The resulting study group of obese men constituted 741 subjects (BMI at selection 33.3 AE 2.3 kg=m 2 ) and the random cohort group consisted of 854 draftees from the same study population (BMI at selection 21.6 AE 2.3 kg=m 2 ). A lean control group (lean control subjects, n ¼ 351) was further selected as the fraction from the random cohort group having a BMI below 25.0 kg=m 2 at the latest examination (BMI 22.9 AE 1.6 kg=m 2 compared to 26.1AE 3.6 kg=m 2 for the entire cohort population at the last examination).
Genomic DNA was obtained from blood samples, drawn at the last examination at the Copenhagen City Heart Study. The study was approved by the Ethical Committee of Copenhagen and was in accordance with the principles of the Declaration of Helsinki II.
Using PCR-RFLP with the enzyme Tsp509I and the polymerase chain reaction (PCR) given primers as in Lin et al 5 a total of 741 obese and 854 control subjects were screened for the Asn363Ser variant. The prevalence of the Ser363 allele was 4.7% (95% CI 3.3 -6.2%) among the obese, 4.1% (2.7 -5.5%) among the random cohort subjects and 4.3% (2.1 -6.5%) among the lean control subjects, respectively, showing no significant differences between the groups (P > 0.1). Furthermore, the GRL genotype had no impact on waisthip ratio or weight gain during an average follow-up of 27.4 AE 8.4 (s.d.) y (Table 1) . Given the allele prevalence of this variant, the current study has a power of more than 95% to detect an association of the variant with BMI. Thus it appears, in contrast to previous studies, 5 that in our population this variant is not associated with measures of obesity.
There could be several reasons for this difference. First of all, this material constitutes only male subjects and it could be hypothesized that the effect seen in the study by Lin et al, 5 could be primarily through an effect of the genetic variant on the female participants. However, the gender distribution in this study was as follows (listed as male : female for genotypes Asn363Asn=Asn363Ser=Ser363Ser, respectively, RCY Lin and BJ Morris, personal communication): group 1 -lean, 56 : 51=2 : 2=0; group-1 -obese, 36 : 28=15 : 0=3 : 2; group 2 -lean, 28 : 35=0=0; group 2 -obese, 19 : 29=8 : 3= 2 : 0. If the samples are separated according to gender, a very clear association between the Ser363 variant and obesity remains when comparing obese and lean men (P < 0.0001 in both groups 1 and 2) but not for women (P ¼ 0.096 and P ¼ 0.8 for groups 1 and 2, respectively). Thus, it appears from the initial study that almost the entire association can be ascribed to the participating men. 7 A recent Swedish study of men did not show any association between obesity and the GRL gene. 7 Secondly, the ascertainment of the subjects in the present study is based on a populational sampling rather than on selected volunteers, which may be a confounding factor in the study of hypertensive obese and controls by Lin et al.
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Absolute allele prevalences vary between the three populations reported, ranging from 3.0% (0.7 -5.3 CI) in The Netherlands 3 to 4.1% (2.7 -5.5% CI) in the Danish (present study), 4.9% (2.3 -7.5% CI) in the Swedish 7 and 6.9% (4.1 -9.7% CI) in the Australian population. 5 Whether these differences represent actual differences in prevalences in the populations (the 95% confidence intervals overlap) is unknown. These studies exemplify the difficulties of the gene hunting research in obesity. 8 In conclusion, the Ser363 polymorphism of the GRL gene is not associated with measures of obesity or weight gain in our population based sample of Danish Caucasian men, indicating that in the examined population this marker is not a relevant predictor of obesity. GRL Ser363 variant and obesity SM Echwald et al
